1. Home
  2. HNST vs DMAC Comparison

HNST vs DMAC Comparison

Compare HNST & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Honest Company Inc.

HNST

The Honest Company Inc.

HOLD

Current Price

$3.25

Market Cap

375.4M

ML Signal

HOLD

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

HOLD

Current Price

$5.64

Market Cap

347.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HNST
DMAC
Founded
2012
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.4M
347.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
HNST
DMAC
Price
$3.25
$5.64
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$3.05
$15.50
AVG Volume (30 Days)
1.7M
139.3K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$371,317,000.00
$500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$3.48
52 Week High
$5.28
$10.42

Technical Indicators

Market Signals
Indicator
HNST
DMAC
Relative Strength Index (RSI) 45.12 38.58
Support Level $3.06 $5.30
Resistance Level $3.71 $7.31
Average True Range (ATR) 0.19 0.32
MACD -0.03 -0.02
Stochastic Oscillator 24.78 9.85

Price Performance

Historical Comparison
HNST
DMAC

About HNST The Honest Company Inc.

The Honest Co Inc is a personal care company dedicated to creating cleanly-formulated and sustainably-designed products for everyone from babies to adults. By combining thoughtful design with science-based innovation, the company delivers personal care products for everyone from babies to adults, spanning categories across wipes, personal care, diapers, and beauty. It has three product categories namely; Diapers and Wipes, Skin and Personal Care, and Household and Wellness, out of which the majority of its revenue is generated from the sale of diapers and wipes. The company operates only in the United States.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: